CDMOs offering Downstream Processing with Gene Therapy
22 published
22 published CDMOs match Downstream Processing and Gene Therapy.
Locations in this set include United States, United Kingdom, China, Japan, Canada, and Denmark.
Capabilities that show up most often in this set: Upstream Processing, CMC Analytical Development, Process Development, Viral Vector Manufacturing, and Cell-Line Development.
Matching companies
AGC BiologicsGlobal CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.
Andelyn BiosciencesCDMO specializing in plasmid DNA and AAV viral vector manufacturing for cell and gene therapy, with digital-first platform emphasizing data integrity and collaboration.
Artis BioSolutionsIntegrated CDMO platform combining proprietary enzymatic synthetic DNA production with advanced therapy development and GMP manufacturing for mRNA, gene editing, viral vectors, cell therapies, and vaccines.
AscendAscend is a gene-to-GMP development partner specializing in advanced biologics and vaccines with 60+ years of custom biologics expertise and 20+ years of AAV development capability. The company offers onsite fill-finish capabilities across multiple US locations and combines next-generation technologies with deep regulatory acumen.
AskBioAskBio is a clinical-stage gene therapy company developing AAV gene therapies for genetic and rare disorders, with a focus on advancing genetic technology and lowering production costs to increase patient access.
BioVectraNorth American CDMO specializing in clinical-to-commercial biologics, small molecules, HPAPIs, and bioreagents with 50+ years of microbial fermentation and complex chemistry expertise across cGMP facilities in Canada.
Boston Institute of Biotechnology, LLCFull-service CDMO offering cGMP and non-GMP mammalian, microbial, gene therapy, and cell therapy manufacturing from preclinical to commercial scale, with bioreactor capacity up to 50,000L.
CatalentGlobal CDMO providing end-to-end contract development and manufacturing for pharma, biotech, and consumer health. Delivers 60+ billion doses annually across small molecules, biologics, cell & gene therapies, and clinical supply.
Cell and Gene Therapy CatapultUK-based innovation and manufacturing support organization for cell and gene therapies, offering infrastructure, expertise, and collaboration across the ATMP lifecycle.
Charles River LaboratoriesCharles River Laboratories provides contract research, development, and manufacturing services across the full drug discovery and development continuum, supporting 80% of FDA-approved drugs over the past five years.
Creative BiogeneCreative Biogene provides viral vector manufacturing, cell line development, and RNA therapeutic platforms including AAV, lentivirus, adenovirus production, circular RNA synthesis, and lipid nanoparticle formulation for gene therapy and vaccine applications.
CuriRx, Inc.CuriRx, Inc. is a Wilmington, Massachusetts contract research and development organization. It offers formulation development, prefilled syringe and lyophilization services, bioprocessing, and analytical testing to pharmaceutical companies of all sizes.
FUJIFILM BiotechnologiesCDMO partner offering end-to-end biologics development and manufacturing from pre-clinical through commercialization, with expertise in cell culture, microbial fermentation, cell and gene therapy, and cGMP manufacturing across US and European facilities.
Forge BiologicsDedicated AAV gene therapy CDMO with a 200,000+ sq. ft. cGMP facility featuring 20 suites and bioreactors up to 5,000L, supporting 60+ clients across 35+ indications with high-yield manufacturing and seamless regulatory compliance.
GenezenViral vector CDMO specializing in AAV, lentiviral, and retroviral manufacturing for gene and cell therapies, with cGMP facilities in Indiana and Massachusetts supporting preclinical through commercial-scale production.
Lonza Cell & Gene TechnologiesLonza is the world's leading CDMO, founded in Switzerland in 1897, serving the healthcare industry with integrated offerings for contract development and manufacturing of therapies across multiple modalities.
National ResilienceEnd-to-end CDMO specializing in complex modalities including cell, gene, and RNA-based therapies with North American manufacturing facilities and development capabilities.
Northway BiotechEnd-to-end CDMO specializing in protein-based biologics and gene therapies, with 20+ years of expertise and cGMP facilities in Lithuania and Massachusetts supporting development from preclinical to commercial stages.
Oxford BiomedicaGlobal viral vector CDMO with 30 years of expertise in lentivirus, AAV, and adenovirus manufacturing. Provides end-to-end development and GMP-compliant manufacturing services from preclinical through commercial launch for cell and gene therapy programs.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Markdown mirror: /explore/downstream-processing/gene-therapy.md